AU2015204446A1 - Internalizing moieties - Google Patents

Internalizing moieties

Info

Publication number
AU2015204446A1
AU2015204446A1 AU2015204446A AU2015204446A AU2015204446A1 AU 2015204446 A1 AU2015204446 A1 AU 2015204446A1 AU 2015204446 A AU2015204446 A AU 2015204446A AU 2015204446 A AU2015204446 A AU 2015204446A AU 2015204446 A1 AU2015204446 A1 AU 2015204446A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
amino acid
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015204446A
Other languages
English (en)
Inventor
Dustin D. Armstrong
Jeffrey C. Way
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valerion Therapeutics LLC
Original Assignee
Valerion Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valerion Therapeutics LLC filed Critical Valerion Therapeutics LLC
Publication of AU2015204446A1 publication Critical patent/AU2015204446A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015204446A 2014-01-13 2015-01-13 Internalizing moieties Abandoned AU2015204446A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461926865P 2014-01-13 2014-01-13
US201461926863P 2014-01-13 2014-01-13
US61/926,863 2014-01-13
US61/926,865 2014-01-13
US201462042771P 2014-08-27 2014-08-27
US201462042755P 2014-08-27 2014-08-27
US62/042,755 2014-08-27
US62/042,771 2014-08-27
PCT/US2015/011269 WO2015106290A1 (en) 2014-01-13 2015-01-13 Internalizing moieties

Publications (1)

Publication Number Publication Date
AU2015204446A1 true AU2015204446A1 (en) 2016-07-14

Family

ID=53524430

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015204446A Abandoned AU2015204446A1 (en) 2014-01-13 2015-01-13 Internalizing moieties

Country Status (7)

Country Link
US (2) US10221250B2 (https=)
EP (2) EP3094646B1 (https=)
JP (2) JP6709733B2 (https=)
AU (1) AU2015204446A1 (https=)
CA (1) CA2936102A1 (https=)
HK (1) HK1231492A1 (https=)
WO (1) WO2015106290A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
CA2907072A1 (en) 2012-03-16 2013-09-19 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of dmpk
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
AU2015204446A1 (en) 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
CA2995673A1 (en) * 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
JP2019535645A (ja) * 2016-09-09 2019-12-12 バレリオン セラピューティクス， エルエルシー ラフォラ病の処置のための方法及び組成物
KR102698752B1 (ko) * 2017-03-20 2024-08-26 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
EP3655432A4 (en) * 2017-07-17 2021-04-14 Nucleus Therapeutics Pty Ltd BINDING PROTEINS 1
US20210137960A1 (en) 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
EP3765062A4 (en) * 2018-03-15 2022-04-13 Valerion Therapeutics, LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYGLUCOUS DISORDERS
CA3111186A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2021042060A1 (en) * 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2021077070A1 (en) 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
CN116529266A (zh) 2020-08-31 2023-08-01 耶鲁大学 用于将核酸递送到细胞的组合物和方法
CN117295753A (zh) 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
AU2022228255A1 (en) 2021-03-03 2023-09-28 Yale University Compositions and methods for treating skeletal muscle disease
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
WO2023168401A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for treating disease
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
US20230303719A1 (en) * 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
AU2023338626A1 (en) 2022-09-09 2025-03-20 Yale University Proteolysis targeting antibodies and methods of use thereof
EP4642488A1 (en) 2022-12-27 2025-11-05 Yale University Antibody drug conjugates
WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
EP4683674A1 (en) 2023-03-23 2026-01-28 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
EP4727979A2 (en) * 2023-06-15 2026-04-22 Caris Science, Inc. Compositions and methods for targeting extracellular dna
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
WO2026011073A1 (en) * 2024-07-03 2026-01-08 Yale University Antibody drug conjugates

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JP2000507225A (ja) * 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
AU2008207948A1 (en) 2007-01-22 2008-07-31 The United States Government As Represented By The Department Of Veterans Affairs Use of antibody conjugates
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
WO2010044894A1 (en) 2008-10-15 2010-04-22 4S3 Bioscience Inc. Methods and compositions for treatment of myotonic dystrophy
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
GB2476671B (en) 2010-01-04 2014-11-26 Plastic Logic Ltd Touch-sensing systems
JP5240316B2 (ja) 2010-10-26 2013-07-17 株式会社デンソー 車両乗員非操作運転システム
WO2012145125A1 (en) 2011-03-25 2012-10-26 4S3 Bioscience Inc. Targeted radionuclides
JP6178785B2 (ja) * 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
WO2012138733A2 (en) 2011-04-05 2012-10-11 Chevron Oronite Company Llc Low viscosity marine cylinder lubricating oil compositions
CA2907072A1 (en) 2012-03-16 2013-09-19 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of dmpk
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
WO2013177428A1 (en) * 2012-05-23 2013-11-28 Valerion Therapeutics, Inc. Methods for increasing muscle contractility
WO2014130722A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of forbes-cori disease
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
AU2015204446A1 (en) 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
WO2015192092A1 (en) 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer

Also Published As

Publication number Publication date
EP3094646B1 (en) 2020-04-15
JP2020096636A (ja) 2020-06-25
US20170174790A1 (en) 2017-06-22
EP3094646A1 (en) 2016-11-23
US10703824B2 (en) 2020-07-07
WO2015106290A1 (en) 2015-07-16
JP2017503511A (ja) 2017-02-02
US10221250B2 (en) 2019-03-05
JP6709733B2 (ja) 2020-06-17
CA2936102A1 (en) 2015-07-16
HK1231492A1 (zh) 2017-12-22
EP3711820A1 (en) 2020-09-23
US20190292276A1 (en) 2019-09-26
EP3094646A4 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
US10703824B2 (en) Internalizing moieties
AU2014218853A1 (en) Methods and compositions for treatment of Forbes-Cori disease
US20210040464A1 (en) Methods and compositions for treatment of polyglucosan disorders
AU2014218854A1 (en) Methods and compositions for treatment of Pompe disease
US20150152170A1 (en) Methods for increasing muscle contractility
US10781433B2 (en) Methods and compositions for treatment of Lafora disease
EP4178615A1 (en) Tetrahedral antibodies
JP2025502229A (ja) 四面体抗体
JP2023545707A (ja) スルホグルコサミンスルホヒドロラーゼ酵素を含む融合タンパク質及びその方法
JP2024546129A (ja) アルファ－ｌ－イズロニダーゼ酵素を含む融合タンパク質及びその方法
US20240239898A1 (en) Modified fcrn binding fragments with improved half-life
US20250250555A1 (en) Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
WO2020077297A1 (en) Methods and compositions for treatment of protein aggregation-based disorders
HK40103089A (zh) 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted